Newsfeeds - Spark Newswire

1 minute read

Editas Medicine Q4 EPS $(0.88) Misses $(0.80) Estimate, Sales $6.54M Beat $3.26M Estimate

February 22, 7:16 AM

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.80) by 10 percent. This is a 44.26 percent decrease over losses of $(0.61) per share from

EDIT

13 minute read

Earnings

Earnings Scheduled For February 22, 2023

By Benzinga Insights

February 22, 6:26 AM

Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.

ACVA

1 minute read

Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock

By Vandana Singh

February 1, 2:03 PM

Cantor Fitzgerald initiated coverage on Editas Medicine Inc (NASDAQ:EDIT) with an Overweight rating and a price target of $15. The analyst says…

CRSP

1 minute read

Shoreline Biosciences Acquires Editas’ iNK Cell Franchise, Related Gene Editing Technologies

By Vandana Singh

January 19, 10:35 AM

Editas Medicine Inc (NASDAQ:EDIT) has agreed to license its proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) and AsCas12a gene editing technologies…

EDIT

1 minute read

SVB Leerink Maintains Market Perform on Editas Medicine, Lowers Price Target to $6

By Benzinga Newsdesk

January 10, 5:29 AM

SVB Leerink analyst Mani Foroohar maintains Editas Medicine (NASDAQ:EDIT) with a Market Perform and lowers the price target from $7 to $6.

EDIT

18 minute read

Options

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

December 22, 2:13 PM

Thursday's session saw 329 companies set new 52-week lows.

ABNB

1 minute read

Citigroup Initiates Coverage On Editas Medicine with Neutral Rating, Announces Price Target of $11

By Benzinga Newsdesk

December 13, 2:10 PM

Citigroup analyst Samantha Semenkow initiates coverage on Editas Medicine (NASDAQ:EDIT) with a Neutral rating and announces Price Target of $11.

EDIT

13 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

December 7, 12:38 PM

Wednesday saw 219 companies set new 52-week lows.

$APE

1 minute read

Gene Editing Stock’s Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment

By Vandana Singh

November 18, 3:51 PM

Credit Suisse has downgraded Editas Medicine Inc (NASDAQ:EDIT) from Outperform to Neutral with a price target of $13 from $25. Thursday, Editas announced…

EDIT

6 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For November 18, 2022

By Benzinga Insights

November 18, 12:58 PM

Upgrades

ABBV